Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
about
Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activationThe LKB1-AMPK pathway: metabolism and growth control in tumour suppressionCardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cellsFatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinibMetformin: multi-faceted protection against cancer.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsAMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy.Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).AMP-activated protein kinase and energy balance in breast cancer.Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.Metformin and cancer: new applications for an old drug.Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.Update on cardiotoxicity of anti-cancer treatments.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.AMPK and Cancer.Metformin is synthetically lethal with glucose withdrawal in cancer cells.The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
P2860
Q28383334-975839EA-A693-47CF-9807-14BCE60B766FQ29617506-92053C1F-E097-4CCE-AAE9-7BEFDCD12EE5Q33352155-16A8FEED-2A02-45BB-9E55-108439E99C1DQ34293099-EA340C05-527A-4D29-83E2-23EC3F3A5CC7Q34613543-0A26AA75-DB0D-41DB-8F3A-EBEDA87972EAQ35029489-A1F662B8-4C32-4A1A-8CD0-A84CB8EBD81AQ35764409-7BE658D0-E1ED-448E-8CD0-1F14E9E403CDQ36396421-97B7E6BD-6DBF-4B30-BBE5-DEC47EC72238Q36479047-373D5857-D6DE-4750-87F6-B51E894A35BDQ36926125-0FD47F13-83BF-45AD-9C37-7A56FFD9D268Q37072265-18D7F61C-61B7-4298-A456-9A6B3A757127Q37539440-7BE4D41C-34F1-458E-BA86-BB41FCE639DDQ37685196-6C704EFE-9C19-4CF8-9259-D358505E2CB7Q37833892-61C22543-B710-44D2-9CBE-C5B92DD51E10Q37837675-9F872EA0-FAC7-4A6E-A775-80D4B6537908Q37889961-8F4A7579-F5AC-4E27-A6E6-8F7760CEB205Q38686222-87714DB5-DA0C-48AD-8AAA-940A3852EB8BQ38812867-F7872BE2-3B2D-433B-9FCE-45ED8756C285Q38998413-2D0775B6-4618-4A51-ACA3-EEB03B6039F6Q39312255-CAEDC649-94E0-49B3-9264-1F86CF87796BQ42808101-5E0F0831-C74B-4507-8533-589162713580Q44312601-FC54AE9C-6A1F-405A-8682-72662C6A9D99Q46157399-30B18A86-E959-4FE9-9A98-5DA70E2DCB03Q47594620-815C5BE7-F0CB-470E-81F4-1C5C7FE5C545Q51348764-0FF492FF-FAB6-4856-8311-E5ABDA6D3090Q57069976-AF6BD49C-D2A6-4C74-908B-2F83609F4136
P2860
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@en
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@nl
type
label
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@en
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@nl
prefLabel
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@en
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@nl
P2093
P356
P1433
P1476
Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
@en
P2093
Karen J Pry
Ljuba Lyass
Patricia B Trusk
Robert L Wappel
Sarah S Bacus
Scott A Shell
P304
P356
10.4161/CC.7.12.6016
P577
2008-06-30T00:00:00Z